BiotechTube

Aurexis® (tefibazumab)

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Staphylococcus Aureus

Conditions

Staphylococcus Aureus

Trial Timeline

Apr 1, 2005 → Jun 1, 2006

NCT ID
NCT00198289

About Aurexis® (tefibazumab)

Aurexis® (tefibazumab) is a phase 2 stage product being developed by Bristol Myers Squibb for Staphylococcus Aureus. The current trial status is completed. This product is registered under clinical trial identifier NCT00198289. Target conditions include Staphylococcus Aureus.

What happened to similar drugs?

2 of 4 similar drugs in Staphylococcus Aureus were approved

Approved (2) Terminated (0) Active (2)
✅Imipenem/cilastatinPfizerApproved
✅linezolid (Zyvox) + vancomycinPfizerApproved
🔄Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + ClindamycinAbbViePhase 3
🔄Ceftobiprole medocaril + DaptomycinBasilea PharmaceuticaPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00198289Phase 2Completed

Competing Products

12 competing products in Staphylococcus Aureus

See all competitors
ProductCompanyStageHype Score
Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + ClindamycinAbbViePhase 3
40
AZD7760AstraZenecaPhase 1/2
39
V710 + PlaceboMerckPhase 2/3
30
DaptomycinMerckPhase 2
35
Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO)MerckPhase 2
35
Imipenem/cilastatinPfizerApproved
39
linezolid (Zyvox) + vancomycinPfizerApproved
43
Linezolid + VancomycinPfizerPre-clinical
26
Aurexis®Bristol Myers SquibbPhase 2
35
blood samples + nasal swabsSanofiPre-clinical
26
Ceftobiprole medocaril + DaptomycinBasilea PharmaceuticaPhase 3
34
514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase IIXBiotechPhase 1/2
22